Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2009

01.05.2009 | Original Article

Serum Level of Adiponectin Correlated with Gender and Genotype in Patients with Chronic Hepatitis C

verfasst von: Qing-Hua Meng, Zhong-Hui Duan, Zun-Hui Lin, Hong-Wei Yu, Juan Li, Ya Liu

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Adiponectin is well recognized as plasma physiologically active polypeptide hormone exclusively derived from human and animal mature adipocytes, with vigorous property in antidiabetic, antiobesity, antiatherogenic, and anti-inflammatory processes. In this study, we investigated the correlation between serum adiponectin level and clinical and pathological parameters in patients with chronic hepatitis C (CHC). The study included 127 patients with CHC and 42 healthy volunteers as controls whose laboratory parameters and serum adiponectin and tumor necrosis factor-α (TNF-α) were assessed using enzyme-linked immunosorbent assay (ELISA). We demonstrated that a lower serum adiponectin level was associated with male gender, higher γ-glutamyltransferase (γ-GGT), higher albumin, higher TNF-α, and steatosis grade. The higher level of serum adiponectin in patients with genotype 2a was demonstrated when compared with that in the patients with genotype 1b. Furthermore, of great interest, results suggested that the significant differences regarding viral genotype seemed to occur only in male patients with CHC but not in female patients. In conclusion, serum adiponectin was associated with gender, genotype, liver steatosis, and TNF-α in a Chinese population with CHC.
Literatur
1.
Zurück zum Zitat Semple RK, Halberg NH, Burling K, et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes. 2007;56:1712–1717. doi:10.2337/db06-1665.PubMedCrossRef Semple RK, Halberg NH, Burling K, et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes. 2007;56:1712–1717. doi:10.​2337/​db06-1665.PubMedCrossRef
11.
Zurück zum Zitat Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006;48:1369–1377. doi:10.1016/j.jacc.2006.06.053.PubMedCrossRef Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006;48:1369–1377. doi:10.​1016/​j.​jacc.​2006.​06.​053.PubMedCrossRef
13.
17.
Zurück zum Zitat Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab. 2005;90:2240–2243. doi:10.1210/jc.2004-1266.PubMedCrossRef Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab. 2005;90:2240–2243. doi:10.​1210/​jc.​2004-1266.PubMedCrossRef
19.
Zurück zum Zitat Wang AY, Hickman IJ, Richards AA, Whitehead JP, Prins JB, Macdonald GA. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol. 2005;100:2717–2723. doi:10.1111/j.1572-0241.2005.00311.x.PubMedCrossRef Wang AY, Hickman IJ, Richards AA, Whitehead JP, Prins JB, Macdonald GA. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol. 2005;100:2717–2723. doi:10.​1111/​j.​1572-0241.​2005.​00311.​x.PubMedCrossRef
21.
24.
Zurück zum Zitat Perumalswami P, Kleiner DE, Lutchman G, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology. 2006;43:780–787. doi:10.1002/hep.21078.PubMedCrossRef Perumalswami P, Kleiner DE, Lutchman G, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology. 2006;43:780–787. doi:10.​1002/​hep.​21078.PubMedCrossRef
25.
Zurück zum Zitat Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology. 2007;46:66–73. doi:10.1002/hep.21703.PubMedCrossRef Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology. 2007;46:66–73. doi:10.​1002/​hep.​21703.PubMedCrossRef
30.
Zurück zum Zitat Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. 2002;35:930–936. doi:10.1053/jhep.2002.32150.PubMedCrossRef Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. 2002;35:930–936. doi:10.​1053/​jhep.​2002.​32150.PubMedCrossRef
37.
38.
Zurück zum Zitat Chuang JH, Wang PW, Tai MH. An adipocentric view of liver fibrosis and cirrhosis. Chang Gung Med J. 2004;27:855–868.PubMed Chuang JH, Wang PW, Tai MH. An adipocentric view of liver fibrosis and cirrhosis. Chang Gung Med J. 2004;27:855–868.PubMed
39.
Zurück zum Zitat Kara B, Gunesacar R, Doran F, Kara IO, Akkiz H. Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection. Adv Ther. 2007;24:972–982. doi:10.1007/BF02877701.PubMedCrossRef Kara B, Gunesacar R, Doran F, Kara IO, Akkiz H. Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection. Adv Ther. 2007;24:972–982. doi:10.​1007/​BF02877701.PubMedCrossRef
40.
Zurück zum Zitat Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load : impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig. 2008;28:9–16. doi:10.2165/00044011-200828010-00002.PubMedCrossRef Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load : impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig. 2008;28:9–16. doi:10.​2165/​00044011-200828010-00002.PubMedCrossRef
41.
Zurück zum Zitat Dal Pero F, Tang KH, Gerotto M, et al. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon-alpha 2a plus ribavirin. J Infect Dis. 2007;196:998–1005. doi:10.1086/521306.PubMedCrossRef Dal Pero F, Tang KH, Gerotto M, et al. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon-alpha 2a plus ribavirin. J Infect Dis. 2007;196:998–1005. doi:10.​1086/​521306.PubMedCrossRef
42.
Zurück zum Zitat Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40 KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol. 2006;44:275–282. doi:10.1016/j.jhep.2005.09.015.PubMedCrossRef Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40 KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol. 2006;44:275–282. doi:10.​1016/​j.​jhep.​2005.​09.​015.PubMedCrossRef
43.
Zurück zum Zitat Howell CD, Jeffers LS, Cassidy W, Reddy KR, Hu S, Lee JS. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J Viral Hepat. 2006;13:371–376. doi:10.1111/j.1365-2893.2005.00697.x.PubMedCrossRef Howell CD, Jeffers LS, Cassidy W, Reddy KR, Hu S, Lee JS. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J Viral Hepat. 2006;13:371–376. doi:10.​1111/​j.​1365-2893.​2005.​00697.​x.PubMedCrossRef
44.
Zurück zum Zitat Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol. 2006;101:2629–2640.PubMed Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol. 2006;101:2629–2640.PubMed
Metadaten
Titel
Serum Level of Adiponectin Correlated with Gender and Genotype in Patients with Chronic Hepatitis C
verfasst von
Qing-Hua Meng
Zhong-Hui Duan
Zun-Hui Lin
Hong-Wei Yu
Juan Li
Ya Liu
Publikationsdatum
01.05.2009
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2009
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0455-z

Weitere Artikel der Ausgabe 5/2009

Digestive Diseases and Sciences 5/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.